HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy

International Journal of Oncology

Volumn 34, Issue 1, 2009, Pages 173-179

  Indrová, Marie ^a   Bieblová, Jana ^a   Rossowska, Joana ^b   Kuropka, Piotr ^c   Pajtasz Piasecka, Elzbieta ^b   Bubeník, Jan ^a   Reinis, Milan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c WROC AW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

Author keywords

Cytotoxicity; HPV16; Tumour infiltrating cells; Vaccines

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; IFOSFAMIDE; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; ANGIOGENESIS INHIBITOR; CHLOROBROMOFOSFAMIDE; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA MODIFICATION; HUMAN PAPILLOMAVIRUS TYPE 16; LYMPHOCYTE COUNT; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; C57BL MOUSE; CYTOTOXICITY TEST; ENZYME IMMUNOASSAY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; GENE THERAPY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PATHOGENICITY; PHYSIOLOGY; TUMOR CELL CULTURE; VIROLOGY; VIRUS INFECTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; GENE THERAPY; HUMAN PAPILLOMAVIRUS 16; HUMANS; IFOSFAMIDE; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; INTERLEUKIN-12; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS INFECTIONS; TUMOR CELLS, CULTURED;

EID: 60749096114     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000139     Document Type: Article

References (30)

1. Yu R, Fujoi K, Tahara H, Araki Y and Yamamoto K: Clonal dynamics of tumour-infiltrating lymphocytes. Eur J Immunol 35: 1754-1763, 2005.
2. Bubeník J, Zeuthen J, Indrová M, Bubenóková D and Símová J: Kimetics and function of peritoneal exudate cells during local IL-2 gene therapy of cancer. Int J Oncol 4: 13-16, 1994.
3. Bubenik J: Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours (review). Curr Cancer Drug Targets 8: 180-186, 2008.
4. + tumour-infiltrating lymphocyte lytic function. J Immunol 177: 1830-1840, 2005.
5. Prins RM, Incardona F, Lau R, Lee P, Claus S, Zhang W, Black KL and Wheeler CJ: Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity. J Immunol 172: 1602-1611, 2004.
6. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H and Zinkernagel RM: Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96: 2233-2238, 1999.
7. Staveley-O'Carroll K, Sotomayor E, Montgomer J, Borrello I, Hwang L, Fein S, Pardoll D and Levitsky H: Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95: 1178-1183, 1998.
8. Dumontet C, Rebbaa A, Bienvenu J and Portoukalian J: Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosides. Cancer Immunol Immunother 38: 311-316, 1994.
9. Preynat-Seauve O, Schuler P, Contassot E, Beermann F, Huard B and French LE: Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol 176: 61-67, 2006.
10. Bukowski RM, Rayman P, Uzzo R, et al: Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 4: 2337-2347, 1988.
11. Kuss I, Saito T, Johnson JT and Whiteside TL: Clinical significance of decreased chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 5: 329-334, 1999.
12. Morford LA, Elliott LH, Carlson SL, Brooks WH and Roszman TL: T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159: 4415-4442, 1997.
13. Reichert TE, Day R, Wagner EM and Whiteside TL: Absent or low expression of the chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58: 5344-5347, 1998.
14. Indrová M, Bieblová J, Jandlová T, Vonka V, Pajtasz-Piasecka E and Reinis M: Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV16-associated MHC class I-proficient and -deficient tumours. Int J Oncol 28: 253-259, 2006.
15. Indrová M, Bieblová J, Bubeník J and Reinis M: IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int J Oncol 32: 499-507, 2008.
16. + T effectors. J Immunol 177: 6962-6973, 2006.
17. Knutson KL and Disis ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy (review). Cancer Immunol Immunother 54: 721-728, 2005.
18. Portielje JE, Gratama JW, van Ojik HH, Stoter G and Kruit WH: IL-12: a promising adjuvant for cancer vaccination (review). Cancer Immunol Immunother 52: 133-144, 2003.
19. Walzer T, Dalod M, Robins SH and Zitvogel L: Natural-killer cells and dendritic cells: 'l' union fait la force' (review). Blood 104: 2252-2258, 2005.
20. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HJ, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996.
21. Mikysková R, Bubeník J, Vonka V, Smahel M, Indrová M, Bieblová J, Simová J and Jandlová T: Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy. Int J Oncol 26: 521-527, 2005.
22. Smahel M, Síma P, Ludvíková V, Marinov I, Pokorná D and Vonka V: Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 21: 1125-1136, 2003.
23. Lahound M, Wrenec D, Boyd RL and Shortman K: Characterization of thymic nurse cell lymphocytes, using an improved procedure for nurse cell isolation. Dev Immunol 3: 103-112, 1993.
24. Indrová M, Reinis M, Bubeník J, Jandlová T, Bieblové J, Vonka V and Velek J: Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol (Praha) 50: 184-193, 2004.
25. Angulo I, de las Heras FG, Garcia-Bustos JF, Gargallo D, Munoz-Fernandez MA and Fresno M: Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95: 212-220, 2000.
26. + T-cell response to peptide vaccination: creation of abeneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30: 40-53, 2007.
27. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131, 2006.
28. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T and Takami T: Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/ macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83: 1136-1144, 2008.
29. Saio M, Radoja, S, Marino M and Frey AB: Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol 167: 5583-5593, 2001.
30. Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, Zhong H, Han B and Ferris R: Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? (review). Cancer Metastasis Rev 25: 333-356, 2006.